About Doron Therapeutics

We believe mobility is a gift. That's why we're dedicated to developing breakthrough biotechnologies that help people with osteoarthritis get moving again.

Our Story

A Journey of Innovation

2023

Doron Therapeutics Founded

Doron is founded as a management-led spinout from Bioventus, a market leader in OA. Doron Therapeutics licensed worldwide rights to MOTYS to continue its development. Recognizing the immense potential of this placental-derived biologic, our team is committed to bringing innovation to those suffering from musculoskeletal pain.

2024

Series A Financing Secured

Closed $11M in series A funding led by SPRIM Global Investments to support the clinical advancement of MOTYS™.

View Press Release →
2025

Fast Track & RMAT Designation Granted by FDA

Received Fast Track & Regenerative Medicine Advanced Therapy (RMAT) designation, recognizing its potential to address serious unmet need in osteoarthritis and validating the robust clinical evidence to date.

View Press Release →
2025

Positive End-of-Phase 2 and Initial RMAT Meeting With FDA

Doron Therapeutics has completed a successful End-of-Phase 2 and initial RMAT meeting with the FDA, confirming the Phase 3 clinical program's design and scope for MOTYS in treating knee osteoarthritis.

View Press Release →
2025

First Patient Dosed in First Phase 3 Trial

With over 350 patients successfully treated in clinical trials, MOTYS™ has entered Phase 3 development. Our singular focus ensures that this breakthrough therapy reaches patients who can benefit from its disease-modifying potential.

View Press Release →
Opportunity

A De-Risked Investment in Innovation

De-Risked Program

More than 350 patients have experienced MOTYS™ in clinical trials, demonstrating its ability to reduce pain, improve mobility, and delay disease progression.

Unparalleled Efficacy

We're confident that MOTYS™ will change the trajectory of osteoarthritis, returning millions of patients to pain-free, active lives.

Singular Focus

Doron Therapeutics was founded with one mission: ensure MOTYS™ becomes both a clinical reality and commercial success.

The Osteoarthritis Crisis

Osteoarthritis is a growing epidemic with no disease-modifying therapies currently available. Prevalence is driven by an aging population, rising obesity rates, and increasing participation in high-impact sports. The need for effective, disease-modifying treatments has never been greater.

16.5B

Second most costly health condition treated at US hospitals

50%

Lifetime risk of symptomatic osteoarthritis

Fastest Growing

Cause of disability worldwide

Leading Cause

Of chronic opioid use in the US

Osteoarthritis Is No Longer Just an "Old Age" Disease

Average age at diagnosis has dropped dramatically over 50 years

80 70 60 50 40
72 1975
55 2025
17 years Earlier onset of OA diagnosis
Our Team

Leadership With Proven Expertise

Our leadership team has collectively brough X+ approved therapies to market across leading biotech and life sciences companies. We bring deep expertise in drug development, clinical trials, and commercialization.

Alessandra Pavesio

Alessandra Pavesio

Co-Founder, Chief Executive Officer

Executive sponsor of the MOTYS™ program at Bioventus. With over 30 years of leadership experience in developing joint preservation technologies at Fidia, Anika, and Bioventus, Alessandra has led six programs in OA and cartilage preservation—all of which have become FDA/CE approved commercial products.

Sarah Caley

Sarah Caley

Co-Founder, Head of Business Development and Strategy

With 20+ years in Business Development and Corporate Strategy, Sarah brings extensive transaction experience to Doron Therapeutics. She has led and completed over 25 successful transactions across multiple verticals for both public and private companies.

MK Kottke

MK Kottke, PhD

Co-Founder, Head of Regulatory and CMC

Regulatory Affairs executive with 25+ years of global experience leading regulatory, toxicology, CMC, and clinical development across pharmaceutical, biotechnology, and medical device programs. Has led U.S. and ex-U.S. regulatory submissions and reviewed CMC, nonclinical, and clinical data to support regulatory review and approval.

Kelli Reifschneider

Kelli Reifschneider

Head of Finance and Business Operations

Experience executing finance and operational work across Fortune 5 companies and early-stage startups for the past 15+ years. Background includes M&A, FP&A, treasury and leading financial diligence for complex healthcare partnerships.

Vicki Gillespie

Vicki Gillespie

AUS Resident Director and Commercial Lead

Experienced Australian operator with a strong track record of managing medical device and pharmaceutical companies and working with both direct and indirect partners. Highly knowledgeable in the area of osteoarthritis in the Australian market.

Alessandra Pavesio

Alessandra Pavesio

Board Member

Previous CSO at Bioventus, Anika and Fidia. Executive Sponsor of MOTYS. Has led key portions of 6 programs in OA/cartilage preservation - ALL of which have become FDA/CE approved commercial products.

Gonzalo Rubio Paris

Gonzalo Rubio Paris

Board Member

Partner, SPRIM Global Investments. Extensive venture capital and company development expertise. Experience in sourcing and leading investments in multiple therapeutic areas.

Karen Zaderej

Karen Zaderej

Board Member

Previously served as Chief Executive Officer and as Chairman of the Board of Directors of Axogen Inc. Led the company's transformation from a start-up to a public company developing a biologically active human tissue graft.

Prof. Jane Fitzpatrick

Prof. Jane Fitzpatrick

Board Observer

International Medical Director. Sports Medicine and Orthopaedics Physician. Expert injector and lecturer on treatment therapies for OA and sports injuries.

Our Approach

We believe in operational efficiency without compromising quality. By partnering with best-in-class contract research organizations, manufacturing partners, and specialized consultants, we maintain agility while leveraging deep expertise across clinical development, regulatory affairs, and commercialization.

Our Partners

Strategic Partners in Innovation

We're proud to partner with leading investors who share our vision of bringing breakthrough therapies to patients with osteoarthritis.

SPRIM Global Investments

SPRIM Global Investments is a privately held investment company providing equity investment, debt, and royalty financing to clinical stage Biotech companies and late-stage MedTech. Led the Series A financing for Doron Therapeutics to advance MOTYS™ through Phase 3 development.

Join Us on This Journey

Whether you're an investor, partner, or potential collaborator, we'd love to connect with you.

Get in Touch Explore the Science